This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05259917
Recruitment Status : Completed
First Posted : March 2, 2022
Last Update Posted : January 31, 2024
Sponsor:
Information provided by (Responsible Party):
KalVista Pharmaceuticals, Ltd.

Brief Summary:
This study is a randomized, double-blind, placebo-controlled, phase III, three-way crossover clinical trial evaluating the efficacy and safety of KVD900, in the treatment of hereditary angioedema attacks in adolescent and adult Patients

Condition or disease Intervention/treatment Phase
Hereditary Angioedema Drug: Placebo Drug: KVD900 600 mg Drug: KVD900 300 mg Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 136 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Three-way Crossover Trial to Evaluate the Efficacy and Safety of Two Dose Levels of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema Type I or II
Actual Study Start Date : February 23, 2022
Actual Primary Completion Date : December 31, 2023
Actual Study Completion Date : December 31, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Placebo Drug: Placebo
Placebo to KVD900 Tablet

Experimental: KVD900 600 mg Drug: KVD900 600 mg
KVD900 Tablet 600 mg (2 x 300 mg)

Experimental: KVD900 300 mg Drug: KVD900 300 mg
KVD900 Tablet 300 mg (1 x 300 mg)




Primary Outcome Measures :
  1. Time to beginning of symptom relief Patient Global Impression of Change (PGI-C) [ Time Frame: within 12 hours of the first investigational medicinal product (IMP) administration. ]
    Time to beginning of symptom relief defined as at least "a little better" (2 time points in a row)


Secondary Outcome Measures :
  1. Time to first incidence of decrease from baseline Patient Global Impression of Severity (PGI-S) (2 time points in a row) [ Time Frame: within 12 hours of the first IMP administration. ]
  2. Time to HAE attack resolution (PGI-S) [ Time Frame: within 24 hours of the first IMP administration. ]
    Time to HAE attack resolution defined as "none"

  3. Proportion of attacks with beginning of symptom relief (PGI-C) [ Time Frame: within 4 hours and within 12 hours of the first IMP administration. ]
    Proportion of attacks with beginning of symptom relief defined as at least "a little better" (2 time points in a row)

  4. Time to at least "better" (2 time points in a row) (PGI-C) [ Time Frame: within 12 hours of the first IMP administration. ]
  5. Time to first incidence of decrease from baseline (2 time points in a row) (PGI-S) [ Time Frame: within 24 hours of the first IMP administration. ]
  6. Time to at least a 50% decrease from baseline (3 time points in a row) Composite Visual Analogue Scale (VAS) [ Time Frame: within 12 hours and within 24 hours of the first IMP administration ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female patients 12 years of age and older.
  • Confirmed diagnosis of HAE type I or II at any time in the medical history.
  • Patient has access to and ability to use conventional on-demand treatment for HAE attacks.
  • If a patient is receiving long-term prophylactic treatment with one of the protocol-allowed therapies, they must be on a stable dose and regimen for at least 3 months prior to the Screening Visit (except for danazol, which requires a stable dose and regimen for 6 months prior to the Screening Visit). Patient must be willing to remain on a stable dose and regimen for the duration of the trial.
  • Patient's last dose of attenuated androgens other than danazol was at least 28 days prior to randomization.
  • Patient:

    1. has had at least 2 documented HAE attacks within 3 months prior to screening or randomization; or
    2. is a completer of the KVD824-201 trial within 3 months prior to randomization and meets all other entry criteria to enroll in KVD900-301
  • Patients must meet the contraception requirements.
  • Patients must be able to swallow trial tablets whole.
  • Patients, as assessed by the Investigator, must be able to appropriately receive and store IMP, and be able to read, understand, and complete the electronic diary (eDiary).
  • Investigator believes that the patient is willing and able to adhere to all protocol requirements.
  • Patient provides signed informed consent or assent (when applicable). A parent or legally authorized representative (LAR) must also provide signed informed consent when required.

Exclusion Criteria:

  • Any concomitant diagnosis of another form of chronic angioedema, such as acquired C1-inhibitor deficiency, HAE with normal C1-INH (previously known as HAE type III), idiopathic angioedema, or angioedema associated with urticaria.
  • A clinically significant history of poor response to bradykinin receptor 2 (BR2) blocker, C1-INH therapy or plasma kallikrein inhibitor therapy for the management of HAE, in the opinion of the Investigator.
  • Use of angiotensin-converting enzyme (ACE) inhibitors after the Screening Visit or within 7 days prior to randomization.
  • Any estrogen containing medications with systemic absorption (such as oral contraceptives including ethinylestradiol or hormonal replacement therapy) within 7 days prior to the Screening Visit.
  • Patients who require sustained use of strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers.
  • Inadequate organ function, including but not limited to:

    1. Alanine aminotransferase (ALT) >2x upper limit of normal (ULN)
    2. Aspartate aminotransferase (AST) >2x ULN
    3. Bilirubin direct >1.25x ULN
    4. International normalized ratio (INR) >1.2
    5. Clinically significant hepatic impairment defined as a Child-Pugh B or C
  • Any clinically significant comorbidity or systemic dysfunction, which in the opinion of the Investigator, would jeopardize the safety of the patient by participating in the trial.
  • History of substance abuse or dependence that would interfere with the completion of the trial, as determined by the Investigator.
  • Known hypersensitivity to KVD900 or placebo or to any of the excipients.
  • Prior participation in trial KVD900-201.
  • Participation in any gene therapy treatment or trial for HAE.
  • Participation in any interventional investigational clinical trial (with the exception of KVD824-201), including an investigational COVID-19 vaccine trial, within 4 weeks of the last dosing of investigational drug prior to screening.
  • Any pregnant or breastfeeding patient.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05259917


Locations
Show Show 66 study locations
Sponsors and Collaborators
KalVista Pharmaceuticals, Ltd.
Investigators
Layout table for investigator information
Study Director: Study Director KalVista Pharmaceuticals, Ltd.
Layout table for additonal information
Responsible Party: KalVista Pharmaceuticals, Ltd.
ClinicalTrials.gov Identifier: NCT05259917    
Other Study ID Numbers: KVD900-301
First Posted: March 2, 2022    Key Record Dates
Last Update Posted: January 31, 2024
Last Verified: January 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Data will not be shared until all global regulatory filings are complete

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by KalVista Pharmaceuticals, Ltd.:
KONFIDENT
Additional relevant MeSH terms:
Layout table for MeSH terms
Angioedema
Angioedemas, Hereditary
Vascular Diseases
Cardiovascular Diseases
Urticaria
Skin Diseases, Vascular
Skin Diseases
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Hereditary Complement Deficiency Diseases
Primary Immunodeficiency Diseases
Genetic Diseases, Inborn
Immunologic Deficiency Syndromes